Rare immune disorder drug tested for long-term safety in tiny study
NCT ID NCT05754450
First seen May 07, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study looks at the long-term safety of a drug called AVTX-803 for people with leukocyte adhesion deficiency type II (LAD II), a rare genetic condition that weakens the immune system. Only 2 participants who completed a previous study can join. Researchers will monitor side effects and measure how well the drug controls the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKOCYTE ADHESION DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Conditions
Explore the condition pages connected to this study.